It is an atypical neuroleptic which reduces the positive and negative symptoms of schizophrenia and will decrease the Parkinson’s symptoms.
It blocks D2 and 5-HT2 receptors and is unlikely to exacerbate the underlying Parkinson’swhile decreasing the positive symptoms.
It is an atypical neuroleptic which reduces positive and negative symptoms without exacerbating the underlying Parkinson’s disease.
It blocks D2 and 5-HT2 receptors, thereby potentially exacerbating the Parkinson’s but reducing the negative symptoms of schizophrenia.
The symptoms are consistent with haloperidol-induced akathisia and tardive dyskinesia and are due to blocked dopamine receptors.
The symptoms are consistent with haloperidol-induced akathisia and tardive dyskinesia and are due to supersensitive dopamine receptors.
These are haloperidol-induced exptrapyramidal symptoms and are due to dual antagonism of D2 and- 5-HT2C receptors.
These are haloperidol-induced exptrapyramidal symptoms and are due to supersensitive D2 and 5-HT2C receptors.
Discontinue Fluphenazine and administer haloperidol
Continue with Fluphenazine and administer an anticholinergic
Continue with Fluphenazine and administer a benzodiazepine
Discontinue Fluphenazine and administer dantrolene